novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout and Cardiovascular Disease (The CARES Trial)

14 Março 2018

Todos os estudos aqui apresentados podem ser consultados na íntegra no site do American College of Cardiology

http://www.acc.org/education-and-meetings/image-and-slide-gallery

Tags:
ACC 2018

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

14 Março 2018
0

Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs - Real World Data Across Three Major World Regions With More Than 400.000 Patients: The CVD-REAL 2 Study

14 Março 2018
0

-->